15 research outputs found
Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience
Females with paired occurrence of cancers in the UADT and genital region have a higher frequency of either Glutathione S-transferase M1/T1 null genotype
Upper Aero digestive Tract (UADT) is the commonest site for the development of second cancer in females after primary cervical cancer. Glutathione S-transferase (GSTM1 and / or T1) null genotype modulates the risk of developing UADT cancer (primary as well as second cancer). The aim of this study was to evaluate the difference in GST null genotype frequencies in females with paired cancers in the UADT and genital region as compared to females with paired cancers in the UADT and non-genital region. Forty-nine females with a cancer in the UADT and another cancer (at all sites-genital and non-genital) were identified from a database of patients with multiple primary neoplasms and were analyzed for the GSTM1 and T1 genotype in addition to known factors such as age, tobacco habits, alcohol habits and family history of cancer. Frequencies of GSTM1 null, GSTT1 null, and either GSTM1/T1 null were higher in females with paired occurrence of cancer in the UADT and genital site (54%, 33% and 75% respectively) in comparison to females with paired occurrence of cancer in the UADT and non-genital sites (22%, 6% and 24% respectively). The significantly higher inherited frequency of either GSTM1/T1 null genotype in females with a paired occurrence of cancers in UADT and genital region (p = 0.01), suggests that these females are more susceptible to damage by carcinogens as compared to females who have UADT cancers in association with cancers at non-genital sites
Original Article - Vanishing bone disease involving the pelvis
Vanishing bone disease is a rare condition characterized by progressive
osteolysis of the bony structures by vascular tissue and their
replacement by fibrous, vascular connective tissue. A 38-year-old lady
who had a previous history of angioma of the left iliac bone presented
with vague symptoms of a limping gait and pain during walking since 2
years duration. The radiologic findings were suggestive of degenerative
changes. A possibility of metastatic disease was also considered.
However the biopsy and Positron emission tomography (PET) scan ruled
out any active disease. Like in most other cases this was possibly a
self-limited disease where bone resorption had spontaneously arrested
Hypofractionated Radiotherapy in Carcinoma Cervix IIIB Tata Memorial Hospital Experience
PURPOSE OF THE STUDY: To analyze the role of hypofractionated
radiotherapy in advanced carcinoma of cervix. BASIC PROCEDURE: Medical
records of 62 women with advanced carcinoma cervix III3 treated during
1994-1996 were reviewed. Patients were treated with standard pelvic
portals to a total dose of 39Gy in 13 fractions over 17 days followed
by intracavitary brachytherapy. Forty-eight patients completed the
planned treatment and were considered suitable for analysis of late
reactions and survival. MAIN FINDINGS: The 5-year disease free
survival was 59% and the overall survival was 50% at the mean follow up
of 40 months. Twenty-one (44%) patients developed acute
gastrointestinal toxicity of which 5 patients had grade III and one
patient had grade IV reaction. Ten patients (21%) developed acute
genitourinary complications, 13 patients (27%) had late rectal
reactions and 10 patients (20%) had late bladder complications. Three
patients had grade I, five had grade II and five had grade III late
rectal toxicity. CONCLUSION: Survival in patients treated
hypofractionated radiotherapy appears comparable to that of standard
fractionation. The acute gastrointestinal and skin reactions were
mainly grade I or grade II. Hypofractionated radiotherapy can certainly
be considered in a select group of patients where the local disease is
extensive and is unsuitable for conventional treatment
Hypofractionated Radiotherapy in Carcinoma Cervix IIIB Tata Memorial Hospital Experience
PURPOSE OF THE STUDY: To analyze the role of hypofractionated
radiotherapy in advanced carcinoma of cervix. BASIC PROCEDURE: Medical
records of 62 women with advanced carcinoma cervix III3 treated during
1994-1996 were reviewed. Patients were treated with standard pelvic
portals to a total dose of 39Gy in 13 fractions over 17 days followed
by intracavitary brachytherapy. Forty-eight patients completed the
planned treatment and were considered suitable for analysis of late
reactions and survival. MAIN FINDINGS: The 5-year disease free
survival was 59% and the overall survival was 50% at the mean follow up
of 40 months. Twenty-one (44%) patients developed acute
gastrointestinal toxicity of which 5 patients had grade III and one
patient had grade IV reaction. Ten patients (21%) developed acute
genitourinary complications, 13 patients (27%) had late rectal
reactions and 10 patients (20%) had late bladder complications. Three
patients had grade I, five had grade II and five had grade III late
rectal toxicity. CONCLUSION: Survival in patients treated
hypofractionated radiotherapy appears comparable to that of standard
fractionation. The acute gastrointestinal and skin reactions were
mainly grade I or grade II. Hypofractionated radiotherapy can certainly
be considered in a select group of patients where the local disease is
extensive and is unsuitable for conventional treatment
Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix
Background: Patients with locally advanced cervical cancer are often
severely distressed with incessant vaginal bleeding, offensive
discharge and pelvic pain and are in some instances are beyond curative
potential. At our institution we routinely use monthly palliative
pelvic radiotherapy for these patients. Methods and Material: One
hundred patients treated between 2000 & 2004 were included in this
analysis. Patients were treated with parallel-opposed pelvic portals
with megavoltage radiation monthly up to a maximum of three fractions
(10Gy/ fraction). Patients with good response after second fraction
were considered for intracavitary brachytherapy delivering 30Gy to
point A. Response was documented with regard to relief of bleeding,
vaginal discharge and pelvic pain. The other aspects evaluated were
patient compliance, disease response, toxicity and survival. Results:
Sixty-eight percent had FIGO stage IIIB, 12% had stage IVA and 14% had
IVB disease. Twenty patients had metastatic disease. The median symptom
duration was 5 months. Majority (67%) presented with vaginal bleeding,
followed by discharge (69%) and pelvic pain (48%). All patients
received at least one fraction of palliative pelvic radiotherapy.
Sixty-one patients received the second fraction and 33 the third. Five
patients received an intracavitary application. The overall response
rates in terms of control of bleeding, discharge and pain were 100%,
49% and 33% respectively. The treatment was generally well tolerated
with a median survival of 7 months. Conclusions: Monthly palliative
pelvic radiotherapy results in satisfactory control of symptoms in
patients with locally advanced carcinoma of cervix with acceptable
complications